Ruxience
These highlights do not include all the information needed to use RUXIENCE safely and effectively. See full prescribing information for RUXIENCE. RUXIENCE (rituximab-pvvr) injection, for intravenous use Initial U.S. Approval: 2019 RUXIENCE (rituximab-pvvr) is biosimilar to RITUXAN (rituximab)
f941fc61-f7a3-4e4a-ab7c-87c1667fa05b
HUMAN PRESCRIPTION DRUG LABEL
Jan 3, 2024
Pfizer Laboratories Div Pfizer Inc
DUNS: 134489525
Products 2
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
rituximab-pvvr
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (7)
rituximab-pvvr
Product Details
FDA regulatory identification and product classification information